Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California. The presentation will take place on Wednesday, June 5, 2024 at 12:00 PM PDT in Theater 3 at the San Diego Convention Center.

The corporate update will highlight Azitra’s updates and progress on its pipeline, including ATR-12 in development for Netherton syndrome and ATR-04 in development for epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity.

Azitra’s presentation details are as follows:

Event: 2024 BIO International Convention Conference Dates: June 3-6, 2024 Presentation Date: Wednesday, June 5, 2024 Presentation Time: 12:00 p.m. PT Venue: San Diego Convention Center in Theater 3 Presenter: Travis Whitfill, Chief Operating Officer

To schedule a meeting with the Company’s management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact James@HaydenIR.com

About Azitra, Inc.

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, timing of the presentation of data for our ATR-12 and ATR-04.

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1b trial for ATR-12 and preclinical studies of other product candidates and obtain required approval before commercialization; the risk that the further data from the ongoing preclinical trials for ATR-04 will not be favorably consistent with the initial preclinical data to date; the risk that the Company’s IND application for ATR-04 may not receive a safe to proceed letter from the FDA; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described in its annual report on Form 10-K filed with the SEC on March 15, 2024. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Norman Staskey Chief Financial Officer staskey@azitrainc.com

Hayden IR James Carbonara (646) 755-7412 james@haydenir.com

Grafico Azioni Azitra (AMEX:AZTR)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Azitra
Grafico Azioni Azitra (AMEX:AZTR)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Azitra